Journal of Anaesthesiology Clinical Pharmacology

LETTER TO THE EDITOR
Year
: 2012  |  Volume : 28  |  Issue : 1  |  Page : 135--136

Response: Fospropofol: Pharmacokinetics?


Girish M Bengalorkar, K Bhuvana, N Sarala, TN Kumar 
 Department of Pharmacology, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka, India

Correspondence Address:
Girish M Bengalorkar
Department of Pharmacology, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka
India




How to cite this article:
Bengalorkar GM, Bhuvana K, Sarala N, Kumar T N. Response: Fospropofol: Pharmacokinetics?.J Anaesthesiol Clin Pharmacol 2012;28:135-136


How to cite this URL:
Bengalorkar GM, Bhuvana K, Sarala N, Kumar T N. Response: Fospropofol: Pharmacokinetics?. J Anaesthesiol Clin Pharmacol [serial online] 2012 [cited 2021 Jun 14 ];28:135-136
Available from: https://www.joacp.org/text.asp?2012/28/1/135/92473


Full Text

Sir,

The pharmacokinetic and pharmacodynamic results of liberated propofol published by Shah et al. could be inaccurate. [1] They have mentioned in their article that they would carry out studies using appropriate assay methods to assess the same and find the degree of error within a period of 12 months. They have not been able to publish the new data and six previously published articles have been retracted. [1] The assay inaccuracy is limited to propofol kinetics only, and therefore, previously published fospropofol kinetics are unaffected. [2]

Time to achieve Cmax of liberated propofol at 12 and 8 min, the volume of distribution of liberated propofol 5.8 l/kg, and the mean terminal phase half life of 2.06 ± 0.77 h for propofol, described in pharmacokinetics in our article, [3] may be inaccurate. Three references (Schywalsky et al., [4] Fechner et al., [5] and Gibiansky et al.[6] ) in our review article [3] have been retracted. Pharmacokinetic data of liberated propofol have been quoted by us from Gibiansky et al only . We wish to bring to your notice that US FDA approval label for fospropofol as on 21-01-2010, which was accessed by the authors on 17-08-2010 and 30-09-2011, about the pharmacokinetics of liberated propofol has not changed till date. [7]

References

1Shah A, Mistry B, Gibiansky E, Gibiansky L. Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation. Anesth Analg 2009;108:382.
2Mueller SW, Moore GD, MacLaren R. Fospropofol Disodium for Procedural Sedation: Emerging Evidence of its Value? Clinical Medicine Insights: Therapeutics 2010;2:513-22.
3Bengalorkar GM, Bhuvana K, Sarala N, Kumar TN. Fospropofol: Clinical Pharmacology. J Anaesth Clin Pharmacol 2011;27:79-83.
4Schywalsky M, Ihmsen H, Tzabazis A, Fechner J, Burak E, Vornov J, et al. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur J Anaesthesiol 2003;20:182-90.
5Fechner J, Ihmsen H, Hatterschild D, Jeleazcov C, Schiessl C, Vornov JJ, et al. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. Anesthesiology 2004;101:626-39.
6Gibiansky E, Struys MM, Gibiansky L, Vanluchene AL, Vornov J, Mortier EP, et al. AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN, part 1: Pharmacokinetics [published correction appears in Anesthesiology 2008;109:940]. Anesthesiology 2005;103:718-29.
7Lusedra (fospropofol disodium) US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov [Last accessed on 2011 Sep 30]